Methoxyphenamine metabolism in rat models of human debrisoquine phenotypes.

The metabolism of the beta 2-adrenoceptor agent methoxyphenamine was investigated in rats of the Lewis and Dark Agouti strains, which are proposed models for human extensive and poor metabolizers of debrisoquine, respectively. Following oral ingestion of 20 mg kg-1 of methoxyphenamine, Dark Agouti excreted, on the average, significantly more methoxyphenamine and less O-demethylmethoxyphenamine and 5-hydroxymethoxyphenamine in 0- to 24-h urine than Lewis. In contrast, the N-demethylation of methoxyphenamine showed no interphenotype differences between the two strains. It is possible that in rats, the form of cytochrome P-450, which controls the 4-hydroxylation of debrisoquine, may also control the O-demethylation and aromatic 5-hydroxylation of methoxyphenamine.

[1]  K. Midha,et al.  METHOXYPHENAMINE AND DEXTROMETHORPHAN AS SAFE PROBES FOR DEBRISOQUINE HYDROXYLATION POLYMORPHISM , 1984, The Lancet.

[2]  L. Bertilsson,et al.  Amitriptyline metabolism: Relationship to polymorphic debrisoquine hydroxylation , 1983, Clinical pharmacology and therapeutics.

[3]  L. Bertilsson,et al.  Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine. , 1983, British journal of clinical pharmacology.

[4]  K. Midha,et al.  Identification of new secondary metabolites of methoxyphenamine in man. , 1983, Xenobiotica; the fate of foreign compounds in biological systems.

[5]  J. Idle,et al.  Animal modelling of human polymorphic drug oxidation—the metabolism of debrisoquine and phenacetin in rat inbred strains , 1981, The Journal of pharmacy and pharmacology.

[6]  K. Midha,et al.  Metabolism of methoxyphenamine in man and in monkey. , 1976, Drug metabolism and disposition: the biological fate of chemicals.